Cytokine-induced killer cell/dendritic cell combined with cytokine-induced killer cell immunotherapy for treating advanced gastrointestinal cancer

Table 2 Subgroup analysis based on cancer type

Outcome	Subgroup	Number of trials	Effect (95%CI)	Overall effect estimate	Heterogeneity
1-Year OS	GC	1	1.54 (0.99, 2.39)	P = 0.056	–
1-Year OS	CRC	2	1.42 (1.21, 1.66)	P < 0.001	I² = 54.1%, P = 0.140
3-Year OS	GC	3	1.29 (1.12, 1.48)	P < 0.001	I² = 0%, P = 0.937
3-Year OS	CRC	2	2.03 (1.41, 2.93)	P < 0.001	I² = 0%, P = 0.782
5-Year OS	GC	2	1.79 (1.31, 2.45)	P < 0.001	I² = 26.8%, P = 0.242
5-Year OS	CRC	2	1.94 (1.18, 3.20)	P = 0.009	I² = 0%, P = 0.634
1-Year PFS	GC	1	1.41 (0.88, 2.26)	P = 0.155	–
1-Year PFS	CRC	2	1.33 (1.11, 1.60)	P = 0.002	I² = 0%, P = 0.940
3-Year PFS	GC	3	1.36 (1.14, 1.61)	P = 0.001	I² = 0%, P = 0.377
3-Year PFS	CRC	2	1.49 (1.10, 2.01)	P = 0.010	I² = 0%, P = 0.980
5-Year PFS	GC	2	2.25 (1.54, 3.29)	P < 0.001	I² = 0%, P = 0.493
5-Year PFS	CRC	2	1.73 (1.19, 2.52)	P = 0.004	I² = 0%, P = 0.854
PR	GC	2	1.58 (0.70, 3.59)	P = 0.275	I² = 0%, P = 0.685
PR	CRC	1	2.52 (0.71, 8.97)	P = 0.154	–
ORR	GC	2	1.30 (0.81, 2.09)	P = 0.278	I² = 0%, P = 0.457
ORR	CRC	1	2.36 (0.79, 7.05)	P = 0.124	–
QOL	GC	1	28 (26.36, 29.64)	P < 0.001	–
QOL	CRC	2	9.32 (6.96, 11.69)	P < 0.001	I² = 0%, P = 0.373

CRC Colorectal cancer, GC gastric cancer, ORR overall response rate, OS overall survival, PFS progression-free survival, PR partial response, QOL quality of life

ISSN: 1471-2407